Medical management of pulmonary disease caused by Mycobacterium avium complex

This publication has 31 references indexed in Scilit:

• First randomised trial of treatments for pulmonary disease caused by M avium intracellulare, M malmoense, and M xenopi in HIV negative patients: rifampicin, ethambutol and isoniazid versus rifampicin and ethambutol
  Thorax, 2001
• Clarithromycin against Mycobacterium avium complex infections
  Tubercle and Lung Disease, 1996
• Activity of Clarithromycin againstMycobacterium aviumInfection in Patients with the Acquired Immune Deficiency Syndrome: A Controlled Clinical Trial
  American Review of Respiratory Disease, 1991
• Diagnosis and Treatment of Disease Caused by Nontuberculous Mycobacteria
  American Review of Respiratory Disease, 1990
• Choice of Antimicrobial Agents forM. aviumDisease Based on Quantitative Tests of Drug Susceptibility
  New England Journal of Medicine, 1990
• In vivo activity of amikacin alone or in combination with clofazimine or rifabutin or both against acute experimental Mycobacterium avium complex infections in beige mice
  Antimicrobial Agents and Chemotherapy, 1988
• MIC as a quantitative measurement of the susceptibility of Mycobacterium avium strains to seven antituberculosis drugs
  Antimicrobial Agents and Chemotherapy, 1988
• Evidence that Antituberculosis Drugs Are Really Effective in the Treatment of Pulmonary Infection Caused byMycobacterium aviumComplex
  American Review of Respiratory Disease, 1988
• Activity of Rifabutin Alone or in Combination with Clofazimine or Ethambutol or Both Against Acute and Chronic ExperimentalMycobacterium intracellulareInfections
  American Review of Respiratory Disease, 1987
• Treatment of Disease Due to Mycobacterium intracellulare
  Clinical Infectious Diseases, 1981